Solano is developing disease-modifying therapeutics to target neurodegenerative diseases by optimizing compounds, which target mitochondria, reduce oxidative damage, and promote neuronal survival. The company’s lead therapeutic compound, XJB-5-131 is being developed for the treatment of Huntington’s, Alzheimer’s and Parkinson’s.
August 14, 2016
VVTom remixes Ambrozious’s new track
May 1, 2013
Behind the scenes on the set of Fly Arm's chart topper "Nest"